SEATTLE, Wash and VANCOUVER, British Columbia, May 9, 2018 — Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisine for smoking cessation, today announced first quarter 2018 financial results and recent highlights.

First-Quarter 2018 Highlights

  • Announced preliminary results from a Phase I/II clinical study evaluating pharmacokinetic (PK) and pharmacodynamics (PD) effects of 1.5mg and 3mg cytisine doses demonstrating an average 58% abstinence rate in healthy volunteer smokers at the end of treatment period
  • Expanded partnership with the University of Bristol for next generation cytisine-based therapies across multiple therapeutic categories
  • Participated in symposia at the Society for Research on Nicotine and Tobacco (SRNT) and at the World Conference on Tobacco or Health (WCTOH)
  • Announced new patent granted on novel formulation of cytisine

“Clinical study results continue to reinforce the established benefit of cytisine as a potential new treatment option for smoking cessation in the U.S.,” commented Rick Stewart, Chairman and Chief Executive Officer of Achieve Life Sciences. “The upcoming meeting with the FDA will aid in finalizing our Phase 3 trial planning and we look forward to the initiation of our Phase 3 clinical trial program later this year.”

University of Bristol Expanded Partnership
In January, Achieve announced an amendment to their Technology License Agreement with the University of Bristol. Achieve has been granted exclusive rights for all human medicinal uses of cytisine derivatives created under the License Agreement across all therapeutic categories. Under the amended collaboration agreement, studies will be conducted to generate and evaluate semi-synthetic cytisine derivatives for potential use in multiple indications across addiction and neurological disorders.

PK/PD Study Results
In February, Achieve announced preliminary results from a study evaluating repeat-dose PK and PD effects of 1.5mg and 3mg cytisine when administered over the standard 25-day course of treatment in 24 healthy volunteer smokers, aged 18-65 years. The PK results indicated expected increases in plasma concentration with higher doses of cytisine. Smokers in the study were not required to have a designated or predetermined quit date, however, 58% of the subjects in the trial achieved biochemically verified smoking abstinence by day 26. Subjects who did not achieve abstinence had a significant reduction in the number of daily cigarettes smoked by the end of treatment. Cytisine was well-tolerated with no serious adverse events reported. The adverse events observed were mostly mild with transient headaches as the most commonly reported event with a slight increase in transient headaches in the 3 mg versus 1.5 mg cytisine dose level. The study is continuing enrollment for subjects aged >65 years.

New Cytisine Patent Granted
In March, a new patent on cytisine succinate salt was granted to Achieve by the UK Intellectual Property Office. Achieve has been pursuing cytisine succinate salt as a novel new drug product formulation that may further enhance cytisine product stability and long term potency. The Company expects to file the pat